Yuki Nakagawa

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 6

Top Topics

Vascular Endothelial Growth Factor

Advanced Non Small Cell Lung Cancer

Renal Cell Carcinoma

Top Venues

Therapeutic innovation & regulatory science

International journal of urology : official journal of the Japanese Urological Association

This page only lists publications with an associated author ORCID identifier.

Publications

Yuki Nakagawa, Takashi Sozu
Improvement of Midpoint Imputation for Estimation of Median Survival Time for Interval-Censored Time-to-Event Data. Therapeutic innovation & regulatory science (2024)
Yuki Nakagawa, Takashi Sozu
Improvement of Midpoint Imputation for Estimation of Median Survival Time for Interval-Censored Time-to-Event Data. Therapeutic innovation & regulatory science 58 (4) (2024)
Kojiro Ohba, Keisuke Monji, Takahiro Osawa, Kazutoshi Yamana, Yosuke Yasuda, Hajime Tanaka, Yuki Nakagawa, Tamaki Fukuyama, Nobuaki Matsubara, Hirotsugu Uemura, Hideki Sakai, Masatoshi Eto
Comprehensive investigation of clinicopathological and immunological features to determine prognostic impact in metastatic renal cell carcinoma: The JEWEL study. International journal of urology : official journal of the Japanese Urological Association (2023)
Kazutoshi Fujita, Go Kimura, Toyonori Tsuzuki, Taigo Kato, Eri Banno, Akira Kazama, Ryo Yamashita, Yuto Matsushita, Daisuke Ishii, Tomoya Fukawa, Yuki Nakagawa, Tamaki Fukuyama, Fumikazu Sano, Yukihiro Kondo, Hirotsugu Uemura
The Association of Tumor Immune Microenvironment of the Primary Lesion with Time to Metastasis in Patients with Renal Cell Carcinoma: A Retrospective Analysis. Cancers 14 (21) (2022)
Makoto Nishio, Haruhiro Saito, Koichi Goto, Satoshi Watanabe, Naoko Sueoka-Aragane, Yusuke Okuma, Kazuo Kasahara, Kenichi Chikamori, Yuki Nakagawa, Tomohisa Kawakami
IMpower132: Atezolizumab plus platinum-based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients. Cancer science 112 (4) (2021)
Yuki Nakagawa, Takuya Yoshimoto, Shintaro Nakagawa, Yasuo Sugitani, Hideharu Yamamoto, Takashi Asakawa
Impact of Tumor Assessment Frequency on Statistical Power in Randomized Cancer Clinical Trials Evaluating Progression-Free Survival. Therapeutic innovation & regulatory science 55 (6) (2021)